Based on our findings, it can be concluded that the addition of CDK4/6 inhibitors to treatment for elderly women with HR+/HER2 subtype metastatic or advanced BC can significantly and non-significantly improve PFS and OS with a similar incidence rate of severe AEs. Here, HR is linked to breast cancer.